



Express Mail Label No.: EV399525733US
Date of Deposit: April 6, 2004

Page 1 of 3

Please type a plus sign (+) in this box



PTO/SB (12-97)
OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/600,132
	Filing Date	06/19/03
	First Named Inventor	Miller and Richon
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	24852-501 CIP

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
XY	A1*	5,055,608	10/08/91	Marks et al.	560	169	06/30/89
	A2*	5,175,191	12/29/92	Marks et al.	514	575	05/14/90
	A3*	5,369,108	11/29/94	Breslow et al.	514	266	10/04/91
	A4*	5,608,108	03/04/97	Marks et al.	562	621	04/17/95
	A5*	5,700,811	12/23/97	Breslow et al.	514	314	05/19/94
	A6*	5,773,474	06/30/98	Breslow et al.	514	616	06/07/95
	A7*	5,932,616	08/13/99	Breslow et al.	514	532	04/04/94
	A8*	6,087,367	06/11/00	Breslow et al.	514	266	05/18/99
	A9*	6,511,990	01/28/03	Breslow et al.	514	314	08/24/00

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
X	B1*	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X	
X	B2*	WO	00/21979	Fujisawa Pharmaceutical Co., LTD	April 20, 2000	X	
X	B3*	WO	00/71703	Methylgene, Inc.	November 30, 2000	X	
Y	B4*	WO	01/18171	Sloan-Kettering Institute for Cancer Research & The Trustees of Columbia University in the City of New York	March 15, 2001	X	
Y	B5*	WO	01/38322	Methylgene, Inc.	May 31, 2001	X	
Y	B6*	WO	01/70675	Methylgene, Inc.	September 27, 2001	X	
Y	B7*	WO	02/22577	Novartis-Erfindungen Verwaltungsgesellschaft M.B.H.	March 21, 2002	X	
Y	B8*	WO	02/30879	Prolifix Limited	April 18, 2002	X	
Y	B9*	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
X	C1*	Andrews et al. (2000). <i>Intl. J. Parasitol.</i> 30: 761-768.
Y	C2*	Archer et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95: 6791-6796.
	C3*	Bhalla et al. (2002). "Co-treatment With The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances the Cytotoxic Effects of Gleevec and Arsenic Trioxide (AT) Against Bcr-Abl Positive Human Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract 4611.
X	C4*	Butler et al. (2000). <i>Cancer Res.</i> 60: 5165-5170.
Y	C5*	Butler et al. (2001). <i>Clinical Cancer Res.</i> 7: 962-970.
Y	C6*	Butler et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> 99: 11700-11705.
Y	C7*	Coffey et al. (2000). <i>Medical and Pediatric Oncology</i> 35: 577-581.

(Did not receive

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
X	C8*	Coffey et al. (2001). <i>Cancer Res.</i> 61 : 3591-3594.
X	C9*	Cohen et al. (1999). <i>Anticancer Res.</i> 19 : 4999-5006.
X	C10*	Cohen et al. (2002). <i>Anticancer Res.</i> 22 : 1497-1504.
X	C11*	Curtin (2002). <i>Exp. Opin. Ther. Patents</i> 12 : 1375-1384.
X	C12*	Dressel (2000). <i>Anticancer Res.</i> 20 : 1017-1022.
Y	C13*	Fei et al. (2002). "Co-treatment With the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Enhances Apo-2L/TRAIL-induced Death Inducing Signaling Complex and Apoptosis of Human Acute Lymphoid Leukemia Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology Abstract No. 4602.
Y	C14*	Feinman et al. (2002). "The Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, Induces Apoptosis of Multiple Myeloma Cells." <i>American Society of Hematology</i> , 44 th Meeting of the American Society of Hematology, Abstract No. 3195.
Y	C15*	Finnin et al. (1999). <i>Nature</i> 401 : 188-193.
X	C16*	Furamai et al. (2001). <i>Proc. Natl. Sci. USA</i> 98 : 87-92.
Y	C17*	Grunstein (1997). <i>Nature</i> 389 : 349-352.
Y	C18*	He et al. (2001). <i>J. Clin. Investigation</i> 108 : 1321-1330.
Y	C19*	Hockly et al. (2003). <i>Proc. Natl. Acad. Sci. USA</i> 100 : 2041-2046.
Y	C20*	Kelly et al. (2001). "Suberoylanilide Hydroxamic Acid (SAHA), a Histone Deacetylase Inhibitor: Biologic Activity Without Toxicity." <i>American Society of Clinical Oncology</i> , Abstract No. 344.
Y	C21*	Kelly et al. (2002). "Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), orally administered has good bioavailability and biologic activity." <i>American Society of Clinical Oncology</i> , 38 th Annual Meeting of the American Society of Clinical Oncology, November 7-10, 2002, Abstract No. 1831.
Y	C22*	Kelly et al. (2002). "A phase I clinical trial of an oral formulation of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)." <i>European J. Cancer</i> 38 (Suppl. 7): 88, Abstract No. 286.
Y	C23*	Kim et al. (1999). <i>Oncogene</i> 18 : 2461-2470.
Y	C24*	Kohge et al. (1998). <i>Biochem. Pharmacol.</i> 56 : 1359-1364.
Y	C25*	Komatsu et al. (2001). <i>Cancer Res.</i> 61 : 4459-4466.
X	C26*	Kouraklis and Theocharis (2002). <i>Curr. Med. Chem. Anti-Cancer Agents</i> 2 : 477-484.
X	C27*	Lee et al. (2001). <i>Cancer Res.</i> 61 : 931-934.
X	C28*	Lin et al. (1998). <i>Nature</i> 391 : 811-814.
X	C29*	Mai et al. (2001). <i>OPPI Briefs</i> 33 : 391-394
X	C30*	Marks et al. (2000). <i>J. of the Natl. Cancer Institute</i> 92 : 1210-1215.
X	C31*	Marks et al. (2001). <i>Clinical Cancer Res.</i> 7 : 759-760.
X	C32*	Marks et al. (2001). <i>Curr. Opin. In Oncology</i> 13 : 477-483.
X	C33*	Marks et al. (2001). <i>Nature Reviews</i> 1 : 194-202.
Y	C34*	Miller et al. (2003). <i>J Med Chem.</i> 46 : 5097-5116.
Y	C35*	Munster et al. (2001). <i>Cancer Res.</i> 61 : 8492-8497.
Y	C36*	O'Connor et al. (2002). "Clinical experience of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in heavily pre-treated patients with aggressive non-hodgkin's lymphoma (NHL0 and hodgkin's disease (HD))." <i>American Society of Clinical Oncology</i> , December 6-10, 2002, Abstract No. 4742.
Y	C37*	Qui et al. (2000). <i>Mol. Biol. Cell</i> 11 : 2069-2083.
X	C38*	Richon et al. (1996). <i>Proc. Natl. Acad. Sci. USA</i> 93 : 5705-5708.
X	C39*	Richon et al. (1998). <i>Proc. Natl. Acad. Sci. USA</i> 95 : 3003-3007.
X	C40*	Richon et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97 : 10014-10019.
Y	C41*	Richon and O'Brien (2002). <i>Clinical Cancer Res.</i> 8 : 662-664.
Y	C42*	Saito et al. (1999). <i>Proc. Natl. Acad. Sci. USA</i> 96 : 4592-4597.
Y	C43*	Sgouros et al. (2002). "Synergistic Interaction of Suberoylanilide Hydroxamic Acid (SAHA) and

x Did not receive

OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
X	/	Radiation in Human Prostate Tumor Spheroids." <i>American Society of Clinical Oncology</i> , Abstract No. 105.
✓	C44*	Stowell et al. (1995). <i>J. Med. Chem.</i> 38: 1411-1413.
✓	C45*	Su et al. (2000). <i>Cancer Res.</i> 60: 3137-3142.
X	C46*	Suzuki et al. (1999). <i>J. Med. Chem.</i> 42: 3001-3003.
✓	C47*	Van Lint et al. (1996). <i>Gene Expression</i> 5: 245-253.
✓	C48*	Vrana et al. (1999). <i>Oncogene</i> 18: 7016-7025.
X	C49*	Webb et al. (1999). <i>J. Biol. Chem.</i> 274: 14280-14287.
✓	C50*	Yoshida et al. (1990). <i>J. Biol. Chem.</i> 265: 17174-17179.
✓	C51*	Yoshida et al. (1995). <i>BioEssays</i> 17: 423-430.
✓	C52*	Zhou et al. (1999). <i>Gene</i> 233: 13-19.
X	C53*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 1056-1061.
✓	C54*	Zhou et al. (2000). <i>Proc. Natl. Acad. Sci. USA</i> 97: 14329-14333.
✓	C55*	Zhou et al. (2001). <i>Proc. Natl. Acad. Sci. USA</i> 98: 10572-10577.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/379,149, filed March 4, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Yevgeny Valenrod/	Date Considered	08/22/2006
--------------------	--------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

X Did not receive